Royalty Pharma (RPRX)
NASDAQ: RPRX
· Real-Time Price · USD
34.90
-0.87 (-2.43%)
At close: Sep 25, 2025, 3:59 PM
35.21
0.89%
After-hours: Sep 25, 2025, 06:41 PM EDT
Royalty Pharma Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financial Royalty Assets Revenue | 550.42M | 539.49M | 1.07B | 533.17M | 512.87M | 541.55M | 523.07M | 508.66M | 501.35M | 664.69M | 546.54M | 551.68M | 515.35M | 511.52M | 526.21M | 505.83M | 503.41M | 529.63M | 524.44M | 498.51M | 474.18M |
| Financial Royalty Assets Revenue Growth | +2.03% | -49.80% | +101.57% | +3.96% | -5.30% | +3.53% | +2.83% | +1.46% | -24.57% | +21.62% | -0.93% | +7.05% | +0.75% | -2.79% | +4.03% | +0.48% | -4.95% | +0.99% | +5.20% | +5.13% | n/a |
| Royalty Income, Other Revenue | 28.25M | 28.76M | 56.2M | 31.52M | 24.4M | 26.43M | 72.77M | 27.4M | 36.66M | 19.14M | 18.92M | 20.71M | 18.07M | 16.94M | 17.83M | 16.54M | 11.42M | 7.34M | 7.3M | 5.33M | 3.31M |
| Royalty Income, Other Revenue Growth | -1.77% | -48.83% | +78.27% | +29.19% | -7.68% | -63.67% | +165.53% | -25.24% | +91.50% | +1.17% | -8.64% | +14.61% | +6.66% | -5.01% | +7.86% | +44.76% | +55.59% | +0.56% | +36.86% | +61.15% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 179.77M | 110.7M | 67.59M | 56.72M | 54.71M | 57.65M | 59.19M | 57.23M | 47.63M | 85.69M | 73.23M | 50.69M | 51.84M | 51.54M | 46.16M | 48.59M | 44.92M | 43.16M | 50.12M | 50.73M | 42.8M | 38.06M | 23.06M | 25.6M | 30.35M | 24.43M |
| Selling, General, and Administrative Revenue Growth | +62.39% | +63.79% | +19.17% | +3.68% | -5.11% | -2.59% | +3.41% | +20.15% | -44.41% | +17.02% | +44.46% | -2.22% | +0.59% | +11.65% | -5.00% | +8.16% | +4.09% | -13.89% | -1.21% | +18.54% | +12.44% | +65.06% | -9.93% | -15.64% | +24.25% | n/a |
| Research and Development Revenue | 300.5M | 50.5M | 500K | 500K | 500K | 500K | 500K | 50.5M | 500K | 500K | 50.5M | 25.5M | 606K | 100.5M | 103.82M | 90.5M | 3.12M | 2.64M | 7.78M | 5.1M | 5.78M | 7.64M | 15.87M | 22.72M | 21.46M | 22.99M |
| Research and Development Revenue Growth | +495.05% | +10000.00% | 0.00% | 0.00% | 0.00% | 0.00% | -99.01% | +10000.00% | 0.00% | -99.01% | +98.04% | +4107.92% | -99.40% | -3.20% | +14.72% | +2798.78% | +18.21% | -66.05% | +52.65% | -11.76% | -24.40% | -51.87% | -30.14% | +5.88% | -6.67% | n/a |